Table 1.
Characteristics of total cohort, 74 patients undergoing HCT
| Patients with characteristic (n), stratified by aGVHD organ involvement (%) |
||||
|---|---|---|---|---|
| Characteristic | Skin only aGVHD |
Gut only aGVHD |
Multi-organ* aGVHD |
No aGVHD |
| Total no. of patients | 11 | 29 | 22 | 12 |
| Age (y) | ||||
| Median | 43 | 47 | 44 | 49 |
| Range | 33–65 | 24–61 | 21–70 | 34–65 |
| Sex | ||||
| Male | 6 (55) | 13 (45) | 9 (41) | 8 (67) |
| Female | 5 (45) | 16 (55) | 13 (59%) | 4 (33) |
| Diagnosis | ||||
| Acute leukemia + MDS | 6 (55) | 18 (62) | 14 (64) | 3 (25) |
| CML + MPD | — | 3 (10) | — | 2 (17) |
| NHL + HL + CLL + MM | 5 (45) | 7 (24) | 7 (32) | 7 (58) |
| Other | — | 1 (4) | 1 (4) | — |
| Conditioning regimen | ||||
| Myeloablative | 6 (55) | 20 (69) | 14 (64) | 5 (42) |
| Reduced intensity | 5 (45) | 9 (31) | 8 (36) | 7 (58) |
| Donor | ||||
| Related | 8 (73) | 21 (72) | 11 (50) | 10 (83) |
| Unrelated | 3 (27) | 8 (28) | 11 (50) | 2 (17) |
| Stem cell source | ||||
| Peripheral blood | 8 (73) | 24 (83) | 13 (59) | 10 (83) |
| Other | 3 (27) | 5 (17) | 9 (41) | 2 (17) |
| HLA | ||||
| Matched | 8 (73) | 27 (93) | 20 (91) | 11 (92) |
| Mismatched | 3 (27) | 2 (7) | 2 (9) | 1 (8) |
| Donor/recipient sex | ||||
| Matched | 8 (73) | 13 (45) | 15 (68) | 9 (75) |
| Mismatched | 3 (27) | 16 (55) | 7 (32) | 3 (25) |
| Female to male | 1 (9) | 4 (14) | 1 (5) | 1 (8) |
| CMV serostatus | ||||
| Recipient/donor | ||||
| Negative/negative | 4 (36) | 8 (28) | 2 (9) | 2 (17) |
| Positive/negative | 3 (27) | 10 (34) | 8 (36) | 2 (17) |
| Negative/positive | 1 (9) | 2 (7) | 3 (14) | 4 (33) |
| Positive/positive | 3 (27) | 9 (31) | 9 (41) | 4 (33) |
| CD34+ (×106/kg) | ||||
| Median | 5.56 | 5.94 | 6.34 | 6.23 |
| Range | 0.04–9.68 | 0.16–10.1 | 0.09–9.99 | 0.56–10.4 |
| aGVHD prophylaxis | ||||
| CSA + methotrexate | 5 (46) | 18 (62) | 13 (59) | 5 (42) |
| CSA/FK506 + MMF | 6 (54) | 11 (38) | 9 (41) | 7 (58) |
| Day + 100 disease status | ||||
| CR or PR | 8 (73) | 26 (90) | 18 (82) | 9 (75) |
| Relapse or progression | 3 (27) | 3 (10) | 4 (18) | 3 (25) |
| Day + 100 survival | ||||
| Alive | 10 (91) | 28 (97) | 22 (100) | 11 (92) |
| Dead | 1 (9) | 1 (3) | — | 1 (8) |
CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; CMV = cytomegalovirus; CR = complete response; CSA = cyclosporine; FK506 = tacrolimus; HL = Hodgkin’s lymphoma; MDS = myelodysplastic syndrome; MM = multiple myeloma; MMF = mycophenolate mofetil; MPD = myeloproliferative disorder; NHL = non-Hodgkin lymphoma; PR = partial response.
*
Liver aGVHD occurred in two patients with multi-organ aGVHD involvement.